← Back to Screener
Gilead Sciences Inc (GILD)
Price$135.87
Favorite Metrics
Price vs S&P 500 (26W)8.71%
Price vs S&P 500 (4W)-9.18%
Market Capitalization$168.21B
P/E Ratio (Annual)19.77x
Indicated Dividend Yield (Annual)2.38%
All Metrics
P/CF (Annual)16.79x
Book Value / Share (Quarterly)$18.29
P/TBV (Annual)26.60x
Indicated Dividend (Annual)$3.16
Revenue Growth (3Y)2.57%
Cash Flow / Share (Quarterly)$7.45
Payout Ratio (TTM)110.04%
Price vs S&P 500 (YTD)8.00%
Gross Margin (TTM)78.83%
Net Profit Margin (TTM)28.91%
EPS (TTM)$6.78
10-Day Avg Trading Volume4.91M
EPS Excl Extra (TTM)$6.78
Revenue Growth (5Y)3.58%
EPS (Annual)$6.78
Dividend / Share (Annual)$3.22
ROI (Annual)17.86%
Gross Margin (Annual)78.84%
Net Profit Margin (5Y Avg)18.22%
Cash / Share (Quarterly)$6.15
P/E Basic Excl Extra (TTM)19.76x
Revenue Growth QoQ (YoY)4.70%
EPS Growth (5Y)133.64%
P/E Normalized (Annual)19.77x
ROA (Last FY)14.42%
Revenue Growth TTM (YoY)2.40%
EBITD / Share (TTM)$8.50
ROE (5Y Avg)23.19%
Operating Margin (TTM)34.04%
Cash Flow / Share (Annual)$7.62
P/B Ratio7.41x
P/B Ratio (Quarterly)6.71x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)6.20x
Net Interest Coverage (TTM)44.73x
ROA (TTM)14.82%
EPS Growth QoQ (YoY)25.14%
EV / EBITDA (TTM)17.11x
EPS Incl Extra (Annual)$6.78
Current Ratio (Annual)1.55x
Quick Ratio (Quarterly)1.06x
3-Month Avg Trading Volume6.88M
52-Week Price Return31.24%
EV / Free Cash Flow (Annual)19.31x
P/E Incl Extra (TTM)19.76x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$4.61
P/S Ratio (Annual)5.71x
Asset Turnover (Annual)0.50x
52-Week High$157.29
Operating Margin (5Y Avg)26.21%
EPS Excl Extra (Annual)$6.78
CapEx CAGR (5Y)-2.83%
Tangible BV CAGR (5Y)-7.13%
26-Week Price Return17.46%
Quick Ratio (Annual)1.06x
13-Week Price Return10.94%
Total Debt / Equity (Annual)1.10x
Current Ratio (Quarterly)1.55x
Enterprise Value$182,541.4
Revenue / Share Growth (5Y)3.72%
Asset Turnover (TTM)0.51x
Book Value / Share Growth (5Y)4.74%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)3.58x
Pretax Margin (Annual)33.27%
Cash / Share (Annual)$6.15
3-Month Return Std Dev28.43%
Gross Margin (5Y Avg)78.00%
Net Income / Employee (TTM)$1
EBITDA CAGR (5Y)17.49%
EBITDA Interim CAGR (5Y)-3.50%
ROE (Last FY)37.49%
Net Interest Coverage (Annual)7.78x
EPS Basic Excl Extra (Annual)$6.78
P/FCF (TTM)18.20x
Receivables Turnover (TTM)6.31x
EV / Free Cash Flow (TTM)19.75x
Total Debt / Equity (Quarterly)1.10x
EPS Incl Extra (TTM)$6.78
Receivables Turnover (Annual)6.31x
ROI (TTM)21.57%
Dividend Growth Rate (5Y)3.30%
P/S Ratio (TTM)5.71x
Pretax Margin (5Y Avg)22.52%
Revenue / Share (Annual)$23.46
Tangible BV / Share (Annual)$4.61
Forward P/E15.89x
Free OCF CAGR (5Y)4.69%
Price vs S&P 500 (52W)-3.86%
P/E Ratio (TTM)19.76x
EPS Growth TTM (YoY)1903.07%
Year-to-Date Return12.14%
5-Day Price Return-1.00%
EPS Normalized (Annual)$6.78
ROA (5Y Avg)8.16%
Net Profit Margin (Annual)28.90%
Month-to-Date Return-1.24%
Cash Flow / Share (TTM)$6.68
EBITD / Share (Annual)$8.28
EPS Growth (3Y)23.06%
Operating Margin (Annual)34.04%
LT Debt / Equity (Annual)0.97x
P/CF (TTM)16.79x
ROI (5Y Avg)10.73%
P/E Excl Extra (TTM)19.76x
LT Debt / Equity (Quarterly)0.97x
EPS Basic Excl Extra (TTM)$6.78
P/TBV (Quarterly)26.60x
Payout Ratio (Annual)47.04%
P/B Ratio (Annual)6.71x
Dividend / Share (TTM)$4.83
Inventory Turnover (TTM)3.58x
Pretax Margin (TTM)33.27%
Book Value / Share (Annual)$18.29
Price vs S&P 500 (13W)8.07%
Net Margin Growth (5Y)125.11%
Dividend Yield (TTM)3.57%
Beta0.39x
P/FCF (Annual)17.79x
Revenue / Share (TTM)$23.52
ROE (TTM)41.02%
52-Week Low$93.37
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.05
4.08
4.05
4.08
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
HALOHalozyme Therapeutics, Inc. | 5.90x | 37.55% | 83.62% | 22.89% | $69.57 |
About
Gilead Sciences develops therapies for life-threatening infectious diseases, with a portfolio focused on HIV and hepatitis B and C. The company's hepatitis C franchise, anchored by Sovaldi, remains a standard of care in combination regimens. Gilead is strategically expanding into oncology through recent acquisitions including CAR-T cell therapy Yescarta/Tecartus and solid tumor therapy Trodelvy.